Carsten Lennerz1, Manish Barman2, Mahmoud Tantawy3, Mark Sopher4, Peter Whittaker5. 1. Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Abteilung für Elektrophysiologie, Faculty of Medicine, Technische Universität München, Munich, Germany; Department of Social Policy, The London School of Economics and Political Science, London, United Kingdom. Electronic address: lennerz@dhm.mhn.de. 2. Cardiology Department, Al Ahli Hospital, Doha, Qatar; Department of Social Policy, The London School of Economics and Political Science, London, United Kingdom. 3. Memorial Souad Kafafi University Hospital, Cardiology Department, Misr University for Science and Technology, 6 of October City, Egypt; Department of Social Policy, The London School of Economics and Political Science, London, United Kingdom. 4. Royal Bournemouth Hospital, Bournemouth, United Kingdom; Department of Social Policy, The London School of Economics and Political Science, London, United Kingdom. 5. Cardiovascular Research Institute, Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, USA; Department of Social Policy, The London School of Economics and Political Science, London, United Kingdom.
Abstract
BACKGROUND: Atrial fibrillation occurs frequently after open-heart surgery. It is associated with increased morbidity and mortality, longer hospital stays, and increased healthcare costs. Prophylactic administration of colchicine may mitigate post-operative atrial fibrillation (POAF). METHODS: We searched PubMed, ClinicalTrials.gov and CENTRAL databases to identify randomized controlled trials (RCTs) that; (1) compared prophylactic use of colchicine to placebo, or usual care, in patients with sinus rhythm who underwent elective open-heart surgery and (2) reported POAF-incidence. We excluded trials focused on incidence of atrial fibrillation after percutaneous interventions or colchicine treatment of diagnosed pericarditis or post-pericardiotomy-syndrome. A random-effects model was used to pool data for POAF-incidence as the primary outcome and for drug-related adverse effects, major adverse events (death and stroke), and hospital length-of-stay as secondary outcomes. RESULTS: We included five RCTs (1412 patients). Colchicine treatment reduced POAF-events by 30% versus placebo or usual care (18% vs. 27%, risk ratio (RR) 0.69, 95% confidence interval (CI) 0.57 to 0.84, p=0.0002). Adverse drug-related effects, especially gastrointestinal intolerance, increased with colchicine; (21% vs. 8.2%, RR 2.52, 95% CI 1.62 to 3.93, p<0.0001). However, major adverse events were unchanged (3.2% vs. 3.2%, RR 0.96, 95% CI 0.48 to 1.95, p=0.92). Length-of-stay decreased by 1.2days with colchicine (95% CI -1.89 to -0.44, p=0.002). CONCLUSION: Colchicine demonstrated superior efficacy versus usual care for prevention of atrial fibrillation after cardiac surgery. Moreover, colchicine treatment was associated with shorter hospital stays. These benefits outweigh increased risk of adverse drug-related effects; although further work is needed to minimize gastrointestinal effects.
BACKGROUND:Atrial fibrillation occurs frequently after open-heart surgery. It is associated with increased morbidity and mortality, longer hospital stays, and increased healthcare costs. Prophylactic administration of colchicine may mitigate post-operative atrial fibrillation (POAF). METHODS: We searched PubMed, ClinicalTrials.gov and CENTRAL databases to identify randomized controlled trials (RCTs) that; (1) compared prophylactic use of colchicine to placebo, or usual care, in patients with sinus rhythm who underwent elective open-heart surgery and (2) reported POAF-incidence. We excluded trials focused on incidence of atrial fibrillation after percutaneous interventions or colchicine treatment of diagnosed pericarditis or post-pericardiotomy-syndrome. A random-effects model was used to pool data for POAF-incidence as the primary outcome and for drug-related adverse effects, major adverse events (death and stroke), and hospital length-of-stay as secondary outcomes. RESULTS: We included five RCTs (1412 patients). Colchicine treatment reduced POAF-events by 30% versus placebo or usual care (18% vs. 27%, risk ratio (RR) 0.69, 95% confidence interval (CI) 0.57 to 0.84, p=0.0002). Adverse drug-related effects, especially gastrointestinal intolerance, increased with colchicine; (21% vs. 8.2%, RR 2.52, 95% CI 1.62 to 3.93, p<0.0001). However, major adverse events were unchanged (3.2% vs. 3.2%, RR 0.96, 95% CI 0.48 to 1.95, p=0.92). Length-of-stay decreased by 1.2days with colchicine (95% CI -1.89 to -0.44, p=0.002). CONCLUSION:Colchicine demonstrated superior efficacy versus usual care for prevention of atrial fibrillation after cardiac surgery. Moreover, colchicine treatment was associated with shorter hospital stays. These benefits outweigh increased risk of adverse drug-related effects; although further work is needed to minimize gastrointestinal effects.
Authors: John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal Journal: Expert Rev Cardiovasc Ther Date: 2018-12-29
Authors: Yao Neng Teo; Yao Hao Teo; Nicholas L Syn; Ming Wei Goh; Celine Shuen Yin Yoong; Chi-Hang Lee; Mark Yan-Yee Chan; Ping Chai; Tiong-Cheng Yeo; Ching-Hui Sia Journal: High Blood Press Cardiovasc Prev Date: 2021-05-18
Authors: Ramzi A Tabbalat; Imad Alhaddad; Ayman Hammoudeh; Yousef S Khader; Hassan Abu Khalaf; Mohammad Obaidat; Jude Barakat Journal: J Int Med Res Date: 2020-07 Impact factor: 1.671
Authors: Panagiotis Korantzopoulos; Konstantinos P Letsas; Gary Tse; Nikolaos Fragakis; Christos A Goudis; Tong Liu Journal: J Arrhythm Date: 2018-06-04